CTP of β-hCG Vaccine

Alternative Name: Carboxy Terminus Peptide of β-human chorionic gonadotropin

Description: Carboxy Terminus Peptide (CTP) of β-human chorionic gonadotropin (β-hCG) was a candidate immunogen to develop immunocontraceptive vaccine for human application.

Product Details

User: Female

Hormonal: No

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: WHO, Talwar Research Foundation

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase II

Active Development: Unknown

Status Details:
  • Phase I trial with a synthetic CTP vaccine was successfully conducted in Australia by the WHO Task Force on Vaccines for Fertility Regulation. Phase II trials were subsequently initiated in Sweden, but stopped due to unacceptable adverse reactions.

Additional Information

References:
  • Steven VC, et al. (1981) Preparation and formulation of a hCG antifertility vaccine: Selection of adjuvant and vehicle. Am J Reprod Immunol Microbiol. 6:315-21.

Footnotes:
  • See also entry on β-hCG vaccine (non-CTP).

Vertical Tabs

Print